Mines Saint-Etienne, Univ Lyon, Univ Jean Monnet, INSERM, U 1059 Sainbiose, Centre CIS, Saint-Etienne, France.
Institut Lumière Matière, Université de Lyon, Villeurbanne, France.
Int J Nanomedicine. 2020 Sep 30;15:7251-7262. doi: 10.2147/IJN.S260640. eCollection 2020.
This study aims at determining lung distribution of gadolinium-based polysiloxane nanoparticles, AGuIX (small rigid platform - SRP), as a potential theranostic approach by the pulmonary route.
First, the aerodynamic size distribution and the aerosol output rate were thoroughly characterized. Then, a multimodal approach using magnetic resonance (MR) and gamma-camera (GC) imaging allows to assess the deposition of the aerosolised nanoparticles in the respiratory tract using isolated ventilated porcine lungs.
The SRP has proven to be radiolabelled by radioisotope with a good yield. Crude SRP or radiolabelled ones showed the same aerodynamic size distribution and output as a conventional molecular tracer, as sodium fluoride. With MR and GC imaging approaches, the nebulised dose represented about 50% of the initial dose of nanoparticles placed in the nebuliser. Results expressed as proportions of the deposited aerosol showed approximately a regional aerosol deposition of 50% of the deposited dose in the lungs and 50% in the upper airways. Each technique assessed a homogeneous pattern of deposited nanoparticles in Lungs. MR observed a strong signal enhancement with the SRP, similar to the one obtained with a commonly used MRI contrast agent, gadoterate meglumine.
As a known theranostic approach by intravenous administration, SRP appeared to be easily aerosolised with a conventional nebuliser. The present work proves that pulmonary administration of SRP is feasible in a human-like model and allows multimodal imaging with MR and GC imaging. This work presents the proof of concept of SRP nebulisation and aims to generate preclinical data for the potential clinical transfer of SRP for pulmonary delivery.
本研究旨在通过肺部途径,确定基于钆的聚硅氧烷纳米颗粒 AGuIX(小刚性平台-SRP)作为潜在治疗方法的肺部分布。
首先,对空气动力学粒径分布和气溶胶输出率进行了全面表征。然后,使用磁共振(MR)和伽马相机(GC)成像的多模态方法,使用隔离通气的猪肺评估气溶胶化纳米颗粒在呼吸道中的沉积。
SRP 已被放射性同位素标记,产率良好。粗 SRP 或放射性标记的 SRP 与常规分子示踪剂(如氟化钠)具有相同的空气动力学粒径分布和输出。通过 MR 和 GC 成像方法,雾化剂量约占放置在雾化器中的纳米颗粒初始剂量的 50%。表示为沉积气溶胶比例的结果表明,沉积剂量的约 50%沉积在肺部,50%沉积在上呼吸道。每种技术评估了沉积在肺部的纳米颗粒的均匀沉积模式。MR 观察到 SRP 具有与常用 MRI 造影剂钆特酸葡甲胺相似的强烈信号增强。
作为一种已知的静脉内给药治疗方法,SRP 似乎很容易通过常规雾化器进行雾化。本工作证明了 SRP 在类似人类的模型中经肺给药是可行的,并允许使用 MR 和 GC 成像进行多模态成像。这项工作提出了 SRP 雾化的概念验证,并旨在为 SRP 经肺给药的潜在临床转化生成临床前数据。